In silico analysis suggests GLP-1 agonists may exacerbate depressive phenotypes and suicidal ideation in patients with hypodopaminergic genetics (Reward Deficiency Syndrome) by further downregulating dopamine signaling.
Double-edged swordGLP-1 drugs may reduce addiction (excess dopamine) but worsen depression/SI (low dopamine) depending on patient genetics
What the researchers found
STRING-MODEL analysis identified 29 relevant genes with GLP1R associations to DRD3, BDNF, CREB1, CRH, IL6, and DPP4. Enrichment analysis revealed connections between candidate genes and depressive phenotypes via dopaminergic signaling. GLP1R agonists may help addiction (hyperdopaminergia) but worsen depression/SI (hypodopaminergia).
Why it matters
Millions are taking GLP-1 drugs, and reports of mood changes and suicidal ideation have emerged. Understanding the genetic basis for who might be vulnerable could enable screening before prescribing and prevent rare but devastating psychiatric side effects.
How the study worked
In silico pharmacogenomic analysis using STRING-MODEL network analysis, gene enrichment analysis, and assessment of 31 refined genes related to semaglutide targets, GLP1R, and suicidal ideation, plus 10 GARS genes.
What this study cannot tell us
Entirely computational (in silico)—no clinical or experimental validation. Theoretical framework needs empirical testing. Associations do not prove causation. GARS test validity is debated.
How to read the evidence
In silico computational analysis—hypothesis-generating only. No clinical or experimental validation. Theoretical framework that requires empirical testing.
When this study was published
Published in 2025; addresses emerging safety concerns about GLP-1 drug neuropsychiatric effects.
The bigger picture
As GLP-1 drugs become among the most prescribed medications globally, understanding their neuropsychiatric effects becomes urgent. This study suggests genetic testing (like GARS) could identify patients at risk for depression or suicidal ideation before starting GLP-1 therapy.
Questions still open
- Should patients be genetically screened for dopamine-related polymorphisms before starting GLP-1 drugs?
- Do clinical data support increased suicidal ideation rates with GLP-1 agonists?
- Can the proposed GLP1R-dopamine pathway be validated experimentally?
Common questions
Can GLP-1 drugs cause depression or suicidal thoughts?
Should I be worried about taking semaglutide?
Read the original research
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder.
Current neuropharmacology, 23(8), 974-995
Citation
Sharafshah, Alireza; Lewandrowski, Kai-Uwe; Gold, Mark S; Fuehrlein, Brian; Ashford, John Wesson; Thanos, Panayotis K; Wang, Gene Jack; Hanna, Colin; Cadet, Jean Lud; Gardner, Eliot L; Khalsa, Jag H; Braverman, Eric R; Baron, David; Elman, Igor; Dennen, Catherine A; Bowirrat, Abdalla; Pinhasov, Albert; Modestino, Edward J; Carney, Paul R; Cortese, Rene; Fiorelli, Rossano Kepler Alvim; Schmidt, Sergio; Pollack, Aryeh R; Badgaiyan, Rajendra D; Blum, Kenneth. (2025). In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder.. Current neuropharmacology, 23(8), 974-995. https://doi.org/10.2174/011570159X349579241231080602